Company: ILTOO PHARMA
Job title: CEO
Jérémie Mariau is a healthcare entrepreneur. For more than 12 years, he worked on moving highly innovative science from bench to bedside across several biopharmaceutical companies. As the CEO of ILTOO Pharma, a clinical-stage biotech company, he pioneered the approach of using Treg agonists as a new mechanistic pathway for the treatment of autoimmune and inflammatory diseases including lupus and type-1 diabetes. Before that, he acted as COO of Alfact Innovation, a French biotech company, focused on developing biotherapies for acute and chronic liver diseases. Jérémie holds a MSc. in human genetics from Paris Diderot University and an Agricultural Engineer degree from Montpellier SupAgro, as well as a master in management of innovation in life science industries from AgroParisTech.
Corelates of Biological & Clinical Response to Low-dose Interleukin-2 in Patients with Systemic Lupus Erythematosus: Results from a Phase-II Proof of Concept Trial 9:00 am
Outline of LUPIL-2, a Phase II Proof of Concept study evaluating ILT-101 in moderate to severe SLE patients Chronic SC administration of ILT-101 is well tolerated ILT-101 treatment clinically improves moderate to severe SLE patients Clinical improvement correlates with Treg stimulation Early Treg activation predicts clinical outcomeRead more
day: Day One